Literature DB >> 28251090

Comparative analysis of the efficacy of astigmatic correction after wavefront-guided and wavefront-optimized LASIK in low and moderate myopic eyes.

Mounir A Khalifa1, Mahmoud F Alsahn2, Mohamed Shafik Shaheen3, David P Pinero4.   

Abstract

AIM: To evaluate and compare the efficacy of the astigmatic correction achieved with laser in situ keratomileusis (LASIK) in eyes with myopic astigmatism using wavefront-guided (WFG) and wavefront-optimized (WFO) ablation profiles.
METHODS: Prospective study included 221 eyes undergoing LASIK: 99 and 122 eyes with low and moderate myopic astigmatism (low and moderate myopia groups). Two subgroups were differentiated in each group according to the ablation profile: WFG subgroup, 109 eyes (45/64, low/moderate myopia groups) treated using the Advanced CustomVue platform (Abbott Medical Optics Inc.), and WFO subgroup, 112 eyes (54/58, low/moderate myopia groups) treated using the EX-500 platform (Alcon). Clinical outcomes were evaluated during a 6-month follow-up, including a vector analysis of astigmatic changes.
RESULTS: Significantly better postoperative uncorrected visual acuity and efficacy index was found in the WFG subgroups of each group (P≤0.041). Postoperative spherical equivalent and cylinder were significantly higher in WFO subgroups (P≤0.003). In moderate myopia group, a higher percentage of eyes with a postoperative cylinder ≤0.25 D was found in the WFG subgroup (90.6% vs 65.5%, P=0.002). In low and moderate myopia groups, the difference vector was significantly higher in the WFO subgroup compared to WFG (P<0.001). In moderate myopia group, the magnitude (P=0.008) and angle of error (P<0.001) were also significantly higher in the WFO subgroup. Significantly less induction of high order aberrations were found with WFG treatments in both low and moderate myopia groups (P≤0.006).
CONCLUSION: A more efficacious correction of myopic astigmatism providing a better visual outcome is achieved with WFG LASIK compared to WFO LASIK.

Entities:  

Keywords:  astigmatism; myopia; wavefront-guided LASIK; wavefront-optimized LASIK

Year:  2017        PMID: 28251090      PMCID: PMC5313554          DOI: 10.18240/ijo.2017.02.17

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN: 2222-3959            Impact factor:   1.779


  27 in total

1.  Wavefront-guided versus wavefront-optimized laser in situ keratomileusis for patients with myopia: a prospective randomized contralateral eye study.

Authors:  Lingmin He; Anthony Liu; Edward E Manche
Journal:  Am J Ophthalmol       Date:  2014-02-19       Impact factor: 5.258

2.  Vector analysis of 1-year astigmatic outcomes from a prospective, randomized, fellow eye comparison of wavefront-guided and wavefront-optimized LASIK in myopes.

Authors:  Brian C Toy; Caroline Yu; Edward E Manche
Journal:  J Refract Surg       Date:  2015-05       Impact factor: 3.573

Review 3.  Meta-analysis of wavefront-guided vs. wavefront-optimized LASIK for myopia.

Authors:  Yifan Feng; Jiguo Yu; Qinmei Wang
Journal:  Optom Vis Sci       Date:  2011-12       Impact factor: 1.973

4.  New method of targeting vectors to treat astigmatism.

Authors:  N A Alpins
Journal:  J Cataract Refract Surg       Date:  1997 Jan-Feb       Impact factor: 3.351

5.  Astigmatism analysis by the Alpins method.

Authors:  N Alpins
Journal:  J Cataract Refract Surg       Date:  2001-01       Impact factor: 3.351

6.  Wavefront-optimized ablation versus topography-guided customized ablation in myopic LASIK: comparative study of higher order aberrations.

Authors:  Hatem E El Awady; Asaad A Ghanem; Sameh M Saleh
Journal:  Ophthalmic Surg Lasers Imaging       Date:  2011-04-28

7.  Evaluation of the efficacy of the Allegretto Wave and the Wavefront-optimized ablation profile in non-anterior astigmatisms.

Authors:  Georgios Labiris; Zisis Gatzioufas; Athanassios Giarmoukakis; Haris Sideroudi; Vassilios Kozobolis
Journal:  Acta Ophthalmol       Date:  2012-06-13       Impact factor: 3.761

8.  Laser in situ keratomileusis using optimized aspheric profiles and cyclotorsion control to treat compound myopic astigmatism with high cylinder.

Authors:  Jorge L Alió; Ana B Plaza-Puche; Lorena M Martinez; Magda Torky; Luis F Brenner
Journal:  J Cataract Refract Surg       Date:  2012-11-03       Impact factor: 3.351

9.  Clinical outcomes of wavefront-guided laser in situ keratomileusis to treat moderate-to-high astigmatism.

Authors:  Steven C Schallhorn; Jan A Venter; Stephen J Hannan; Keith A Hettinger
Journal:  Clin Ophthalmol       Date:  2015-07-13

10.  Comparison of Wavelight Allegretto Eye-Q and Schwind Amaris 750S excimer laser in treatment of high astigmatism.

Authors:  Maja Bohac; Alma Biscevic; Mateja Koncarevic; Marija Anticic; Nikica Gabric; Sudi Patel
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-08-23       Impact factor: 3.117

View more
  4 in total

1.  Consistent comparison of angle Kappa adjustment between Oculyzer and Topolyzer Vario topography guided LASIK for myopia by EX500 excimer laser.

Authors:  Ming-Shen Sun; Li Zhang; Ning Guo; Yan-Zheng Song; Feng-Ju Zhang
Journal:  Int J Ophthalmol       Date:  2018-04-18       Impact factor: 1.779

2.  Wavefront excimer laser refractive surgery for adults with refractive errors.

Authors:  Shi-Ming Li; Meng-Tian Kang; Ning-Li Wang; Samuel A Abariga
Journal:  Cochrane Database Syst Rev       Date:  2020-12-18

3.  Comparison between Wavefront-optimized and corneal Wavefront-guided Transepithelial photorefractive keratectomy in moderate to high astigmatism.

Authors:  Ikhyun Jun; David Sung Yong Kang; Samuel Arba-Mosquera; Jin Young Choi; Hyung Keun Lee; Eung Kweon Kim; Kyoung Yul Seo; Tae-Im Kim
Journal:  BMC Ophthalmol       Date:  2018-06-26       Impact factor: 2.209

4.  A Comparison between Wavefront-Optimized and Wavefront-Guided Photorefractive Keratectomy in Patients with Moderate-to-High Astigmatism: A Randomized Clinical Trial.

Authors:  Hassan Razmjou; Alireza Peyman; Saeedreza Moshfeghi; Hamideh Kateb; Morteza Naderan
Journal:  J Curr Ophthalmol       Date:  2022-07-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.